ciprofloxacin has been researched along with simvastatin in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bharate, SS; Vishwakarma, RA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Sawant, RD | 1 |
| Ammori, BJ; Ashcroft, DM; Darwich, AS; Jamei, M; Pade, D; Rostami-Hodjegan, A | 1 |
| Agheli, S; Aminabadi, NA; Huang, B; Jamali, Z; Samiei, M; Shirazi, S | 1 |
| Boyle, JG; Brogan, A; Goldie, FC | 1 |
| Asgary, S; Heydari, P; Parham, S; Zargar Kharazi, A | 1 |
| Kassie, GM; Kerr, M; Moffat, A; Pratt, N; Roughead, EE | 1 |
| Alsubih, M; Balakrishnan, D; El Morabet, R; Khan, AR; Khan, NA; Khan, RA; Khan, S; Khoo, KS; Mubashir, M | 1 |
1 review(s) available for ciprofloxacin and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for ciprofloxacin and simvastatin
| Article | Year |
|---|---|
A Randomized Trial Using 3Mixtatin Compared to MTA in Primary Molars with Inflammatory Root Resorption: A Novel Endodontic Biomaterial.
Topics: Aluminum Compounds; Anti-Bacterial Agents; Calcium Compounds; Cefixime; Child; Child, Preschool; Ciprofloxacin; Crowns; Dental Fistula; Dental Pulp Diseases; Dental Restoration, Permanent; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Metronidazole; Molar; Oxides; Periapical Diseases; Pulp Capping and Pulpectomy Agents; Pulpectomy; Root Canal Filling Materials; Root Resorption; Silicates; Simvastatin; Tooth, Deciduous; Treatment Outcome; Zinc Oxide-Eugenol Cement | 2016 |
17 other study(ies) available for ciprofloxacin and simvastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin.
Topics: Aged; Anti-Infective Agents; ATP-Binding Cassette Transporters; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypolipidemic Agents; Rhabdomyolysis; Simvastatin | 2009 |
A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution.
Topics: Administration, Oral; Bariatric Surgery; Biological Availability; Chemistry, Pharmaceutical; Ciprofloxacin; Computer Simulation; Cytochrome P-450 CYP3A; Diclofenac; Fluconazole; Humans; Intestinal Mucosa; Models, Biological; Obesity, Morbid; Omeprazole; Permeability; Pharmaceutical Preparations; Simvastatin; Solubility | 2012 |
Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Middle Aged; Rhabdomyolysis; Simvastatin | 2016 |
Comparing the wound healing effect of a controlled release wound dressing containing curcumin/ciprofloxacin and simvastatin/ciprofloxacin in a rat model: A preclinical study.
Topics: Animals; Anti-Bacterial Agents; Bandages; Ciprofloxacin; Curcumin; Delayed-Action Preparations; Rats; Simvastatin; Wound Healing | 2022 |
Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Amlodipine; Amphotericin B; Australia; Case-Control Studies; Ciprofloxacin; Diclofenac; Furosemide; Humans; Ibuprofen; Metformin; Naproxen; Omeprazole; Primary Health Care; Ramipril; Simvastatin; Spironolactone; Sulfamethoxazole; Telmisartan; Trimethoprim; Valacyclovir; Zoledronic Acid | 2022 |
Comparison of constructed wetland performance coupled with aeration and tubesettler for pharmaceutical compound removal from hospital wastewater.
Topics: Acetaminophen; Animals; Carbamazepine; Ciprofloxacin; Erythromycin; Hospitals; Ibuprofen; Lorazepam; Pharmaceutical Preparations; Simvastatin; Waste Disposal, Fluid; Wastewater; Wetlands | 2023 |